Balaxi Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Balaxi Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	25.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost

Feb 10

Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet

Feb 09

Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

Aug 08

The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested

May 20

Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 12

Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 27

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Balaxi Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:BALAXI - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	2,621	-52	N/A	N/A	N/A
9/30/2023	2,879	-106	-199	-99	N/A
6/30/2023	3,196	-95	N/A	N/A	N/A
3/31/2023	3,364	460	-70	61	N/A
12/31/2022	3,449	506	N/A	N/A	N/A
9/30/2022	3,200	545	262	362	N/A
6/30/2022	3,038	511	N/A	N/A	N/A
3/31/2022	2,794	477	288	341	N/A
12/31/2021	2,416	433	N/A	N/A	N/A
9/30/2021	2,457	421	31	56	N/A
6/30/2021	2,373	401	N/A	N/A	N/A
3/31/2021	2,313	381	-13	0	N/A
12/31/2020	1,939	312	N/A	N/A	N/A
9/30/2020	1,411	228	-53	-39	N/A
6/30/2020	938	138	N/A	N/A	N/A
3/31/2020	456	61	-142	-140	N/A
12/31/2019	416	53	N/A	N/A	N/A
9/30/2019	342	40	-93	-93	N/A
6/30/2019	230	31	N/A	N/A	N/A
3/31/2019	140	20	-15	-15	N/A
12/31/2018	79	11	N/A	N/A	N/A
9/30/2018	15	-3	N/A	N/A	N/A
6/30/2018	N/A	-8	N/A	N/A	N/A
3/31/2018	N/A	-8	-7	-7	N/A
12/31/2017	-6	-12	N/A	N/A	N/A
9/30/2017	-6	-11	N/A	N/A	N/A
6/30/2017	-6	-8	N/A	N/A	N/A
3/31/2017	0	-2	N/A	-1	N/A
12/31/2016	0	-1	N/A	N/A	N/A
9/30/2016	0	-1	N/A	N/A	N/A
6/30/2016	0	-1	N/A	N/A	N/A
3/31/2016	0	-1	N/A	0	N/A
12/31/2015	2	-1	N/A	N/A	N/A
3/31/2015	2	1	N/A	2	N/A
3/31/2014	2	1	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BALAXI's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if BALAXI's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if BALAXI's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BALAXI's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if BALAXI's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BALAXI's Return on Equity is forecast to be high in 3 years time

Balaxi Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Balaxi Pharmaceuticals Limited Appoints Mahesh Inani as the Compliance Officer

Balaxi Pharmaceuticals Limited Announces Resignation of Purnima Singh Kamble as Independent Director

Balaxi Pharmaceuticals Limited Announces Resignation of Udayan Shukla as Company Secretary and Compliance Officer

New major risk - Share price stability

Insufficient new directors

New minor risk - Share price stability

Third quarter 2024 earnings released: EPS: ₹13.29 (vs ₹8.21 in 3Q 2023)

Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost

Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet

Independent Non-Executive Director exercised options to buy ₹30m worth of stock.

Second quarter 2024 earnings released: EPS: ₹14.10 (vs ₹15.49 in 2Q 2023)

Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

Balaxi Pharmaceuticals Limited (NSEI:BALAXI) agreed to acquire Balaxi Healthcare Ecuador S.A.S. for $0.04 million.

First quarter 2024 earnings released: ₹40.49 loss per share (vs ₹14.15 profit in 1Q 2023)

Balaxi Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2023

Full year 2023 earnings released: EPS: ₹45.81 (vs ₹47.66 in FY 2022)

Investor sentiment improves as stock rises 17%

The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested

A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Board Member exercised options to buy ₹2.7m worth of stock.

Second quarter 2023 earnings released: EPS: ₹15.49 (vs ₹12.05 in 2Q 2022)

Now 20% undervalued

Now 20% undervalued

Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹14.15 (vs ₹10.71 in 1Q 2022)

Investor sentiment improved over the past week

Balaxi Pharmaceuticals Limited, Annual General Meeting, Jul 11, 2022

Investor sentiment deteriorated over the past week

Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively

Full year 2022 earnings released: EPS: ₹47.66 (vs ₹38.14 in FY 2021)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS ₹12.05 (vs ₹10.12 in 2Q 2021)

Second quarter 2022 earnings released: EPS ₹12.05 (vs ₹10.12 in 2Q 2021)

First quarter 2022 earnings released: EPS ₹10.71 (vs ₹8.70 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹38.14 (vs ₹8.12 in FY 2020)

Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Financial Controller recently sold ₹3.3m worth of stock

Independent Director has left the company

Investor sentiment improved over the past week

Balaxi Pharmaceuticals Limited Announces Resignation of Rakesh Khanna as an Additional Director (Independent Category)

Independent Non-Executive Director recently bought ₹1.4m worth of stock

Investor sentiment improved over the past week

New 90-day low: ₹579

Third quarter 2021 earnings released: EPS ₹10.96

New 90-day low: ₹615

Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Market pulls back on stock over the past week

Market pulls back on stock over the past week

First half earnings released

New 90-day high: ₹946

New 90-day high - ₹401

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies